10 assets in Chromophobe Renal Cell Carcinoma

Therapeutic assets addressing Chromophobe Renal Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Chromophobe Renal Cell Carcinoma	Bradley A. McGregor, MD	P2	B (57)
Ipilimumab Chromophobe Renal Cell Carcinoma	Bradley A. McGregor, MD	P2	CCC (53)
Nivolumab Chromophobe Renal Cell Carcinoma	Bradley A. McGregor, MD	P2	CCC (53)
nn3201 Chromophobe Renal Cell Carcinoma	Novelty Nobility, Inc.	P1	CC (43)
Cytokine Induced Memory-Like Natural Killer Cells Chromophobe Renal Cell Carcinoma	Dana-Farber Cancer Institute	Early P1	C (39)
13C-Fructose Chromophobe Renal Cell Carcinoma	University of Texas Southwestern Medical Center	N/A	D (30)
Acetic-1-13C Acid Chromophobe Renal Cell Carcinoma	University of Texas Southwestern Medical Center	N/A	D (30)
Glucose, Anhydrous Chromophobe Renal Cell Carcinoma	University of Texas Southwestern Medical Center	N/A	D (30)
Glutamine Chromophobe Renal Cell Carcinoma	University of Texas Southwestern Medical Center	N/A	D (30)
Lactate Chromophobe Renal Cell Carcinoma	University of Texas Southwestern Medical Center	N/A	D (30)